GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Tech companies back AI support in recruitment, underscore rising importance of AI literacy
Some spoke of concerns they have over prospective employees using AI in their applications.
Nikolaos Fertakis returns to HSBC Malta as interim Chief Risk Officer
Nikolaos Fertakis previously served as HSBC Bank Malta’s Chief Operating Officer.
The circular economy conversation is shifting, agency CEO says
Keeping materials in use for longer is no longer just about waste reduction, he said.
Emmanuel Agius appointed President of the St John’s Co-Cathedral Foundation
This marks the fourth occasion on which he has been appointed to this role.
